The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
The presentations underscore the company’s deep expertise in dermatology and immunology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
